Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Other Working Capital Changes for 18 consecutive years, with $59.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 184.05% year-over-year to $59.4 million; the trailing twelve-month figure through Jun 2026 stood at $221.3 million (up 477.87% YoY), and the FY2025 full-year result was $117.7 million, up 401.95% from the prior year.
• Other Working Capital Changes grew to $59.4 million in Q2 2026 per ALNY's latest filing, from $6.3 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $24.5 million in Q3 2023 and bottomed at -$190.9 million in Q2 2024.
• Historically, Other Working Capital Changes has averaged -$16.5 million across 5 years, with a median of -$10.6 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes soared 1252.83% in 2022, then plunged 1517.23% in 2023.
• Over 5 years, Other Working Capital Changes stood at -$8.7 million in 2022, then soared by 607.0% to $44.0 million in 2023, then sank by 115.35% to -$6.8 million in 2024, then jumped by 1150.15% to $71.0 million in 2025, then declined by 16.37% to $59.4 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $59.4 million, $6.3 million, and $71.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.